Rôle de la thrombospondine-1 dans le développement des maladies rénales
Open Access
- 20 December 2013
- journal article
- abstracts
- Published by EDP Sciences in médecine/sciences
- Vol. 29 (12) , 1131-1137
Abstract
Thrombospondin-1 (TSP-1) is a 450-kDa matricellar glycoprotein. By its various domains, it can interact with various partners and exhibit anti-angiogenic, pro-apoptotic and immunomodulatory activities. TSP-1 is also a major endogenous activator of the pro-fibrotic growth factor TGF-β. In healthy adult renal parenchyma, TSP-1 expression is very scarce and limited to Bowman's capsule and interstitium. During nephropathies, many cell types can express or secrete TSP-1 (mesangial, endothelial, smooth muscle, tubular cells, podocytes and fibroblasts) depending on the nature of injury and the evolutive stage of the disease. Inhibition of the different domains of TSP-1 using specific antibodies or peptides, blockade of TSP-1 expression by antisense oligonucleotides and use of knock-out mice, allowed to identify the role of TSP-1 in various models of experimental nephropathy. All these studies demonstrated a deleterious effect of TSP-1 on renal repair by inducing TGF-β and fibrosis, decreasing VEGF and capillary density, and enhancing inflammatory cells recruitment. Thus, TSP-1 represents a potential therapeutic target for the management of chronic kidney diseases.Keywords
This publication has 41 references indexed in Scilit:
- Blockade of TSP1-Dependent TGF-β Activity Reduces Renal Injury and Proteinuria in a Murine Model of Diabetic NephropathyThe American Journal of Pathology, 2011
- Thrombospondin-1 Contributes to Mortality in Murine Sepsis through Effects on Innate ImmunityPLOS ONE, 2011
- GTP Cyclohydrolase I/BH4 Pathway Protects EPCs via Suppressing Oxidative Stress and Thrombospondin-1 in Salt-Sensitive HypertensionHypertension, 2010
- Thrombospondin-1 Inhibits VEGF Receptor-2 Signaling by Disrupting Its Association with CD47Journal of Biological Chemistry, 2010
- Angiotensin II sustains brain inflammation in mice via TGF-βJournal of Clinical Investigation, 2010
- Thrombospondin‐1 modulates vascular endothelial growth factor activity at the receptor levelThe FASEB Journal, 2009
- Deficiency of thrombospondin-1 reduces Th17 differentiation and attenuates experimental autoimmune encephalomyelitisJournal of Autoimmunity, 2009
- Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapiesNature Reviews Cancer, 2009
- Modulation of Macrophage Activation State Protects Tissue from Necrosis during Critical Limb Ischemia in Thrombospondin-1-Deficient MicePLOS ONE, 2008
- Thrombospondins: from structure to therapeuticsCellular and Molecular Life Sciences, 2008